# Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

> **NCT00756951** · PHASE2 · COMPLETED · sponsor: **SciClone Pharmaceuticals** · enrollment: 59 (—)

## Conditions studied

- Oral Mucositis
- Head and Neck Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** SCV-07
- **DRUG:** SCV-07

## Key facts

- **NCT ID:** NCT00756951
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 59 (—)
- **Last updated:** 2009-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00756951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00756951, "Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00756951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*